Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372741 | 0.87 | TSHR (0.33) | TSHR | |
| SCHEMBL17431124 | 0.86 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL1746 | 0.79 | — | — | |
| SCHEMBL5544690 | 0.79 | MEN1 (0.42) | MEN1KMT2A | |
| SCHEMBL7097725 | 0.79 | — | — | |
| SCHEMBL24209093 | 0.78 | — | — | |
| SCHEMBL24693021 | 0.77 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL24733089 | 0.77 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL21802590 | 0.77 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL7967516 | 0.77 | MEN1 (0.32) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112262166-A | Polyurethane foam-forming compositions | 速的奥公司 | 2021-01-22 | — | — | CN | claimed |
| EP-3578541-B1 | COMPOSITIONS COMPRISING MOLECULES HAVING PESTICIDAL UTILITY, AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2023230649-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023115165-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115166-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115167-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| EP-3215172-B1 | MODIFICATIONS AND USES OF CONOTOXIN PEPTIDES | KINETA CHRONIC PAIN LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11618772-B2 | Modifications and uses of conotoxin peptides | KINETA CHRONIC PAIN, LLC | 2023-04-04 | — | — | US | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-11014970-B2 | Modifications and uses of conotoxin peptides | KINETA CHRONIC PAIN, LLC (US) | 2021-05-25 | — | — | US | disclosed |
| EP-0956292-A1 | CONANTOKINS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1999-11-17 | — | — | EP | disclosed |
| US-5871572-A | COLORANT, WATER, A WATER-SOLUBLE ORGANIC SOLVENT, AND PECTIC ACID | SEIKO EPSON CORPORATION (JP) | 1999-02-16 | — | — | US | disclosed |
| EP-0838508-A2 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORPORATION (JP) | 1998-04-29 | — | — | EP | disclosed |
| US-5719280-A | REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID | SYNTEX (U.S.A.) INC. (US) | 1998-02-17 | — | — | US | disclosed |
| WO-1998003189-A1 | USE OF CONANTOKINS | COGNETIX, INC. (US) | 1998-01-29 | — | — | WO | disclosed |
| WO-1998003541-A1 | CONANTOKINS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1998-01-29 | — | — | WO | disclosed |
| EP-0757677-A1 | BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1997-02-12 | — | — | EP | disclosed |
| US-5538988-A | CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. | 1996-07-23 | — | — | US | disclosed |
| WO-1995029165-A2 | BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-11-02 | — | — | WO | disclosed |
| WO-1994001396-A1 | PHENYL AMIDINE UREA DERIVATIVES AS PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618772-B2 | Modifications and uses of conotoxin peptides | CHRNA9, CHRNA10, CHRNA7 | MEN1 3713/4885KMT2A 2642/4885TSHR 1327/4885 |
| US-11014970-B2 | Modifications and uses of conotoxin peptides | CHRNA9, CHRNA10, CHRNA7 | MEN1 3713/4885KMT2A 2642/4885TSHR 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.